CD274 and liposarcoma: A phase I/II study has evaluated anti-PDL1 avelumab combined with trabectedin in 33 patients with advanced liposarcoma and LMS, with an ORR of 13%, a DCR of 56% (3 PR, 10 SD) and a median PFS of 8.3 months [98].